Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung14: first-line osimertinib with or without datopotamab deruxtecan in EGFR-mutated advanced or metastatic non-small cell lung cancer
CTR20241813Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2024; status: active.
02
Drugs
datopotamab deruxtecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241813.